Clinical

Dataset Information

0

40-301 : Special Drug Use-Results Survey of ADLUMIZ


ABSTRACT: Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors [Efficacy]Body weight increasing effect and appetite increasing effect

DISEASE(S): Cancer Cachexia: Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Cancer, Large Intestine Canc

PROVIDER: 2613087 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2613085 | ecrin-mdr-crc
2021-05-06 | GSE159159 | GEO
2024-04-15 | GSE250341 | GEO
2024-05-22 | GSE239375 | GEO
2013-07-31 | E-GEOD-47068 | biostudies-arrayexpress
2010-06-24 | GSE21335 | GEO
2013-07-31 | GSE47068 | GEO
2023-10-01 | GSE220756 | GEO
2019-07-25 | GSE134817 | GEO
| EGAD00010001499 | EGA